EQS-News 101 0 Kommentare Immunic to Participate in Investor and Scientific Conferences in May

Für Sie zusammengefasst

Immunic to participate in investor and scientific conferences in May
Presenting data on clinical trials for chronic inflammatory diseases
Lead development program includes phase 3 and phase 2 trials for MS

Issuer: Immunic AG / Key word(s): Conference
Immunic to Participate in Investor and Scientific Conferences in May

06.05.2024 / 12:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

Immunic to Participate in Investor and Scientific Conferences in May

NEW YORK, May 6, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in May:

May 12-14 and 21-22: Bio€quity Europe 2024. Jessica Breu, Vice President Investor Relations and Communications at Immunic, will attend and host one-on-one investor meetings at this conference taking place in San Sebastián, Spain and virtually. To schedule a meeting, please use the Bio€quity conference portal or contact Jessica Breu at: jessica.breu@imux.com.
May 18-21: Digestive Disease Week (DDW) 2024. Franziska Buriánek, M.D., Senior Medical Director at Immunic, will present data from Immunic’s phase 1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6 (Sirtuin 6), in patients with celiac disease, in an oral presentation at this conference in Washington, DC. The presentation will be accessible on the “Events and Presentations” section of Immunic’s website at: https://ir.imux.com/events-and-presentations.
Presentation Title: First In Human Trial Of IMU-856, An Orally Available Epigenetic Modulator Of Barrier Regeneration For The Treatment Of Celiac Disease
Abstract ID: 4025905
Session Title: Since Sliced Bread: Best in Celiac 2024
Session Type: Research Forum
Session Date: Monday, May 20, 2024
Session Time: 2:00 - 3:30 pm EDT
May 29- June 1: The Consortium of Multiple Sclerosis Centers (CMSC) 38^th Annual Meeting. Robert J. Fox, M.D., Staff Neurologist, Mellen Center for Multiple Sclerosis, Vice-Chair for Research, Neurological Institute, Cleveland Clinic, Cleveland, Ohio will present interim data from Immunic’s phase 2 CALLIPER trial of lead asset, nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838) at this meeting in Nashville, TN. The poster presentation will be accessible on the “Events and Presentations” section of Immunic’s website at: https://ir.imux.com/events-and-presentations.
Poster Title: Impact of Vidofludimus Calcium on Serum Neurofilament in Progressive MS: Assessment from the CALLIPER Interim Analysis
Abstract ID: 9651
Poster Session Date: Thursday, May 30, 2024
Poster Session Time: 5:15 - 7:15 pm CDT (6:15 - 8:15 pm EDT)
May 30 - June 2: XXIII National Congress of Neurology. Sonya Ivanova Hristova-Chakmakova, M.D., Assistant Professor, Multiprofile Hospital for Active Treatment in Neurology and Psychiatry «St. Naum», Sofia, Bulgaria, will present data from Immunic’s phase 2 CALLIPER trial in an oral presentation at this conference in Golden Sands, Bulgaria. The presentation will be accessible on the “Events and Presentations” section of Immunic’s website at: https://ir.imux.com/events-and-presentations.
Presentation Title: Impact of Vidofludimus Calcium (VidoCa) on Serum Neurofilament Light Chain (NfL) Levels in Patients with Progressive Multiple Sclerosis: Interim Data from the CALLIPER Trial
Poster ID: 201
Poster Session: 2
Date: Thursday, May 30, 2024
Time: 2:00pm EEST (7:00am EDT)